1034688-78-2

Basic information

• Product Name: 5-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indole
• Synonyms: 5-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indole
• CAS NO: 1034688-78-2
• Molecular Weight: 353.808
• Mol File: 1034688-78-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 5-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indole(1034688-78-2)
• EPA Substance Registry System: 5-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indole(1034688-78-2)

Safety Data

• Hazardous Substances Data: 1034688-78-2(Hazardous Substances Data)

Upstream product

• 1379308-93-6 N-hydroxy-1H-indole-4-carboximidamide 
• 213598-07-3 3-chloro-4-isopropoxy-benzoic acid 
• 163797-89-5 N-hydroxy-1H-indole-5-carboximidamide 

Downstream Products

• 1034687-12-1 sodium 3-[5-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indol-1-yl]propanoate 
• 1034688-80-6 ethyl 3-[5-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indol-1-yl]propanoate 
• 1034687-28-9 3-[5-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indol-1-yl]-2,2,3-trifluoropropanoic acid 
• 1034689-35-4 3-bromo-5-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indole 
• 1034688-82-8 3-chloro-5-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indole 

Relevant articles and documents

S1P RECEPTORS MODULATORS

The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.